Navigation Links
XDR-TB a Serious Threat to India

The study, the first in India to look at the prevalence of XDR-TB, found this type of TB accounts for 8% of multi-drug-resistant cases, compared with about 4% in the United States.

MDR-TB (multi-drug resistant TB) describes strains of tuberculosis that are resistant to at least the two first-line TB drugs, isoniazid and rifampicin. XDR-TB is MDR-TB that is also resistant to three or more of the six classes of second-line drugs. XDR-TB leaves patients (including many people living with HIV) virtually untreatable using currently available anti-TB drugs.

Recent findings from a survey conducted by the World Health Organization and the Centers for Disease Control and Prevention found that XDR-TB has been identified in all regions of the world but occurs most frequently in the countries of the former Soviet Union and in Asia.

Sushil Jain of the Hinduja National Hospital in Mumbai, India, and colleagues examined 3,904 lab samples at their hospital, and found that 1,274 were positive for Mycobacterium tuberculosis. Of these, 32% were found to be MDR-TB, out of which 8% were XDR-TB.

Tuberculosis can infect many sites in the body but most commonly affects the lungs. All XDR-TB cases were in patients with pulmonary tuberculosis, or TB found in the lungs, which can be spread by coughing, sneezing, laughing or singing. Repeated exposure to someone with TB disease is generally necessary for infection to take place.

The death rate of XDR-TB patients in the study was 42%, which Dr. Jain calls "alarmingly high."

"An important finding was that the majority of patients with XDR-TB were of younger age group (their average age was 30 years), thus posing a major threat to our economically productive population," Dr. Jain notes. "Serious efforts are needed to tackle this deadly disease which may become a global emergency." Dr. Jain says that XDR-TB has long existed in India but has been under-re cognized and under-treated.

"Most labs in India are not equipped to perform drug susceptibility tests so exact prevalence is difficult to ascertain, and treatment in the absence of reliable sensitivity reports is difficult. Compounding the problem is the huge costs of treating these most difficult TB patients," he said.


'"/>




Related medicine news :

1. WHO and U.S. Officials Meet to Discuss Funding to Combat XDR-TB
2. Forcible Detention and Isolation Needed for XDR-TB Patients, warn Experts
3. World Must Act Quickly To Control Spread XDR-TB
4. XDR-TB: the Latest Global Terror
5. Kenya, Surrounding Region Lack Capacity To Handle XDR-TB, Experts Say
6. Socialization A Serious Trouble For Childhood Cancer Survivors
7. Viagra May Be Useful For Serious Lung Disease
8. Mountain Biking Results In Serious Injuries
9. Breast Cancer More Serious For Younger Patients
10. Rahul Mahajans Condition Is Serious But Stable : Hospital
11. Africans Should Take Their Traditional Medicine Very Seriously
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: